NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

This is not “approval” it is conditional access. There is a big difference because of case by case review. Those who are considered to be best suited candidates will receive a chance for greater access. This does look like an expansion of indications that can apply for funding but each indication will likely be reviewed for certain biomarkers that indicate a greater probability of successful outcome so that funding produces the most benefit per £ spent. Kind of a rational way to approach healthcare and yes this is a big deal; ). Best wishes.

No, it is neither.

What it says is that the NHE may elect to fund approved drugs on a patient by patient basis outside of any funding provided by reason of a NICE opinion, CDF or IDF.

They make clear that this path is an exception as otherwise they are "line jumping" (my term) the others in the system who only get funded per the general funds.

And it would not fund off-label (unless cheaper than the alternative).